News - Starpharma

Latest News

AGM Chairman’s address and CEO’s presentation

Nov 21st, 2019

Melbourne, Australia: Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 4.00pm today.

VivaGel® condom receives regulatory approval in Europe

Nov 20th, 2019

Starpharma today announced that it has been granted marketing approval for the VivaGel^® condom in Europe.

2019 AGM details

Nov 19th, 2019

Starpharma today notifies that its 2019 AGM will be held at 4pm on 21 November 2019 at RACV City Club, Level 2, 501 Bourke Street, Melbourne, Victoria.

The AGM will be recorded and available via webcast later that day. To access the webcast, participants can register via the following link:

https://webcasting.boardroom.media/broadcast/5dccc1f06242591605116cb6

UK launch of VivaGel® BV

Nov 13th, 2019

Starpharma today announced that VivaGel^® BV has been launched in the UK under the brand Betafem^® BV Gel. This launch follows the first European launches in June 2019, including in Germany and other countries.

In the media

Starpharma’s VivaGel® BV regulatory approvals continue in Asia

Sep 3rd, 2019

Finance News Network reported Starpharma received further regulatory approval in another Asian country for its breakthrough product for bacterial vaginosis, VivaGel^® BV. The news follows the first approval in the region announced on 15 August.

Read the full news coverage here.

Update on Starpharma’s latest positive interim DEP® trial results, VivaGel® and upcoming milestones

Aug 30th, 2019

Online news outlet Boardroom Media interviewed Starpharma CEO Dr Jackie Fairley following the release of its annual report and full-year results. In the interview, Dr Fairley shared the company’s latest DEP^® trial results, as well as VivaGel^® and upcoming milestones.

To listen to the full interview, click here.

Starpharma sees positive results in ovarian cancer treatment

Aug 29th, 2019

Online investor news outlet Finance News Network reported Starpharma’s positive results for its novel HER-2 targeted DEP^® conjugate (ADC) which outperformed the leading HER-2 ADC, Kadcyla^®, in a human ovarian cancer model.

To watch the full news video, click here.

Promising efficacy signals for Starpharma’s DEP® trials

Aug 28th, 2019

Biotech trade publication noted Starpharma announced promising efficacy signals in its ongoing clinical trials for both DEP^® cabazitaxel and DEP^® docetaxel.

To read the full article, click here.